Abbott Partners With ALZpath To Advance Blood-Based Alzheimer's Testing

June 24, 2026 — 10:33 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - ALZpath Inc., a blood test-based diagnostic solutions company for Alzheimer's disease, announced that it has signed a licensing agreement with Abbott Laboratories (ABT) to incorporate ALZpath's proprietary phosphorylated Tau 217 antibody to develop an in vitro diagnostic, or IVD test, for Alzheimer's disease.

The agreement will allow the test design to be utilized on Abbott's Alinity ci-series immunoassay system, thereby increasing access to early detection of the disease.

Plasma tau phosphorylated at the threonine-217 residue (pTau217) is a blood-based biomarker that studies have shown can accurately differentiate individuals with Alzheimer's disease (AD) from those with non-AD neurodegenerative disorders.

The pTau217 antibody offers a scalable alternative to AD's current gold standard biomarkers, cerebrospinal fluid (CSF) analysis and amyloid-ß PET (Aß-PET) imaging, which are invasive and expensive.

ABT is currently trading at $92.46, up 2.14%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Abbott Partners With ALZpath To Advance Blood-Based Alzheimer's Testing

Tags

Latest Articles